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Endometrial cancerObjective. PD-L1 and PD-1 are predictive markers for immunotherapy and increasingly relevant in endome-
trial cancer. The reported fraction of positive primary tumors has been inconsistent.We investigated the expres-
sion of PD-L1 and PD-1 in primary tumors, also stratified by MSI. As immunotherapy is foremost relevant for
metastatic disease, PD-L1 and PD-1 expression was also assessed in corresponding metastatic lesions.
Methods. PD-L1 and PD-1 was investigated in a prospective, population based endometrial cancer cohort of
700 patients with corresponding metastatic lesions from 68 and 74 patients respectively. Fresh tissue was
used for gene expression analysis.
Results. In primary tumors, PD-L1 and PD-1 are expressed in 59% and 63%, respectively, but with no impact on
survival, nor when stratified for MSS andMSI. Expression patterns of PD-L1 and PD-1 are similar inMSI andMSS
tumors. Availablemetastatic lesions showheterogeneous expression of PD-L1 and PD-1. In gene expression anal-
ysis several genes related to immunological activity, including CD274 (encoding for PD-L1), were upregulated in
PD-1 positive tumors.
Conclusion. PD-L1 and PD-1 are frequently expressed in endometrial cancer and expression patterns are sim-
ilar across MSS and MSI tumors. Expression in corresponding metastatic lesions is discordant compared to pri-
mary tumors. These findings are in particular relevant for treatment decisions in advanced and recurrent disease.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Endometrial cancer is the most common gynecological malig-
nancy in the Western world, and the incidence is increasing due
to the higher prevalence of obesity and the longer life expectancy
[1,2]. Although the prognosis is generally good, about 15–20% of
patients experience recurrence and little improvement in survival
has been achieved the last decades for advanced, recurrent andrs CCBIO, Department of Clinical
stad).
. This is an open access article undermetastatic disease. Chemotherapy has been the standard of care
with modest response rates [3]. In recent years, treatment with im-
mune checkpoint inhibitors has emerged as a major therapeutic
modality in oncology [4]. After the FDA approved pembrolizumab
(PD-1-inhibitor) for treatment of microsatellite instable recurrent
and metastatic endometrial cancer, treatment with immune check-
point inhibitors has become an option also for endometrial cancer
patients [5]. The KEYNOTE-028 study with pembrolizumab given
to PD-L1 positive, advanced MSI-high endometrial cancer has dem-
onstrated promising results [6]. However, the expression patterns
of PD-L1 and PD-1 in primary tumors and metastases in particular
have not been fully explored in endometrial cancer.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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receptor PD-1 on tumor-infiltrating CD4 and CD8 T-cells. Binding of PD-
L1 to PD-1 suppresses the T-cell, a negative feedback system that re-
presses the immune system [5]. Blockade of this pathwaywith antibod-
ies to PD-L1or PD-1,which re-activates the immune systemhas become
an increasingly used treatment modality with promising response rates
in the recurrent and metastatic setting in solid tumors. Results have
demonstrated less toxicity than chemotherapeutic regimens and often
more durable responses [7–9]. In endometrial cancer, immune check-
point inhibitors to PD-L1 and PD-1 are increasingly studied and they
are an attractive option for treatment [10]. TCGA (The Cancer Genome
Atlas) classified endometrial cancer into four distinct molecular sub-
types and gave momentum to further research on targeted therapy
[11]. One of the four identifiedmolecular subtypes, themicrosatellite in-
stable (MSI) tumors has demonstrated increased mutational burden
that creates numerous neo-antigens responsible for the immune re-
sponse. MSI has become an established predictive marker for response
to immunotherapy in solid tumors [12–14], and PD-1 blockade has
demonstrated better response rates in tumors with mismatch-repair
deficiency compared with mismatch repair-proficient cancers [15].
However, only 20–30% of endometrial cancer patients are MSI-high,
making only a fraction eligible for treatment with immune checkpoint
inhibitors using this stratification [11]. Anti-tumor activity was demon-
strated in a study with combination therapy with pembrolizumab and
lenvatinib (VEGF-inhibitors) to biomarker unselected advanced endo-
metrial cancer, supporting that treatment with immune checkpoint in-
hibitors may not only be reserved for MSI-high patients [16]. Also,
promising results with combination therapy with PD-1 blockade and
cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) to MSS-tumors
have been reported [17].
The expression of PD-L1 and PD-1 in endometrial cancer has previ-
ously been described in primary tumors in smaller cohorts, however,
the previously described rates of expression in primary tumors have
been inconsistent [18–20]. Moreover, the expression of PD-L1 and PD-
1 in corresponding metastatic lesions has to our knowledge not been
investigated in endometrial cancer. Expression patterns in metastatic
lesions are of particular importance as treatment with immune check-
point inhibitors has been of foremost relevance in the recurrent and
metastatic setting. We aimed to investigate the expression of PD-L1
and PD-1 in primary tumors and corresponding metastatic lesions in
both microsatellite stable and instable cancers, in relation to clinico-
pathological characteristics and follow-up.2. Materials and methods
2.1. Patient samples
Patients included in the study were all diagnosed and treated at
Haukeland University Hospital, Bergen, Norway and diagnosed
with endometrial cancer from 2001 to 2015. All samples included
in the study were retrieved from the Bergen Biobank for Gynecolog-
ical Cancer (REK number 2014/1907). The biobank was collected
prospectively after patients had given informed written consent.
All parts of the study has been approved according to Norwegian leg-
islation andWestern Regional Committee for Medical and Health Re-
search Ethics (REK 2009/2315 and 2014/1907). All patients were
staged according to FIGO 2009 criteria and clinical data and follow-
up were obtained from clinical records as previously described
[21]. Formalin-fixed paraffin embedded (FFPE) tissue from 689 and
737 was used for immunohistochemistry for expression of PD-L1
and PD-1, respectively. Additionally, 275 corresponding metastases
from 68 patients were assessed for PD-L1 expression, and 273 corre-
sponding metastases from 74 patients were assessed for PD-1 ex-
pression. Number of corresponding metastases from each patient
ranged from one to eight. Transcriptional alterations related to PD-L1 and PD-1 protein expressionwere investigated bymRNAmicroar-
ray analysis for 260 freshly frozen samples.
2.2. Immunohistochemistry
Tissue microarrays (TMAs) from FFPE were constructed as previ-
ously described [22]. Briefly, the area with highest tumor grade was
identified on hematoxylin and eosin stained slides. Tissue cylinders of
0.6 mm were punched out and mounted in a paraffin block using a
custom-made precision instrument (Beecher Instruments, Silver Spring,
MD, USA). Three cylinders were punched for primary tumors and one
cylinder for metastatic lesions. TMA slides (5 μm) were cut and
dewaxed with xylene and rehydrated in ethanol before microwave an-
tigen retrieval in target retrieval solution, pH 6 for PD-L1 and pH 9 for
PD-1, MSH6 and PMS2. Following peroxidase block, the TMAs were in-
cubated for 1 h at room temperature with rabbit monoclonal antibody
to PD-L1 (1:100; no. E1L3N, Cell Signaling, Danvers, MA, USA) or rabbit
monoclonal antibody to PD-1 (1:300; no. D4W2J, Cell Signaling, Dan-
vers, MA, USA) followed by 30 min of incubation with secondary HRP-
conjugated anti-rabbit antibody and 8minwith DAB-chromogen (EnVi-
sion detection system, Dako, Glostrup, Denmark). Mouse monoclonal
antibody to PMS2 (1:25; no PMS2-L-CE; Leica Biosystems, Wetzlar,
Germany) and mouse monoclonal antibody to MSH6 (1:25; no MSH6-
L-CE; Leica Biosystems, Wetzlar, Germany) were incubated for 1 h
before incubationwith secondaryHRP-conjugated anti-mouse antibody
for 30min in room temperature and finally 3minwith DAB-chromogen
(EnVision detection system, Dako, Glostrup, Denmark). Sections were
counterstained in hematoxylin before dehydration and mounting. The
immunostained sectionswere reviewed by lightmicroscopy and scored
visually by a semiquantitative and subjective method.
2.3. Evaluation of staining
Evaluation of stainingwas performed blinded for the clinical charac-
teristics and outcome. For PD-L1, a staining index was calculated as a
product of staining intensity (0–3) and area of positive tumor cells
(1 b 10%, 2= 10%–50% and 3 N 50%). No expressionwas seen in stroma,
and subsequently only glandular expression was evaluated. Expression
was mainly cytoplasmic, however some membranous localization was
seen and a score was given irrespectively of cellular localization of PD-
L1. In subsequent statistical analyses, indexeswere grouped in quartiles,
considering the size of the subgroups and the number of events in each
category. Quartile division was selected according to similarity in sur-
vival in each quartile. The lower quartile corresponded to negative
(staining index = 0) expression only, quartile 2 to 4 were merged to-
gether and subsequently cut offwasnegative/positive. For PD-1, expres-
sion was evaluated as positive when N5% of stromal staining was
detected. Two independent observers evaluated 88 cases and the κ-
value was 0.74 for PD-L1 and 0.72 for PD-1. MSI tumors were identified
by loss of one of the twomismatch-repair proteins, MSH6 and PMS2 by
immunohistochemical staining according the published Promise classi-
fier [23,24]. Positive stromal staining was used as internal control. For
MSH6 and PMS2, stainingwas defined as negativewhen b10% glandular
stainingwas observed. For negative caseswith no stromal staining (lack
of positive control), full sections were stained to determine status
[23,24]. If either MSH6 or PMS2 was negative, cases were defined as
negative and thus MSI.
2.4. Gene expression analysis
Gene expression alterations in relation to PD-L1 and PD-1 expres-
sion were investigated in previously generated microarray gene ex-
pression data from 260 primary endometrial cancers. RNA was
extracted from fresh frozen tissue using the RNeasyMini Kit (Qiagen,
Hilden, Germany) and hybridised to Agilent Whole Human Genome
Microarrays 44k (Cat.no. G4112F), according to the manufacturer's
262 H. Engerud et al. / Gynecologic Oncology 157 (2020) 260–267instructions [25]. Overlapping data on both gene expression and IHC
was available from 221 patients and were used in subsequent analysis.
The expression datawere normalised using quantile normalisation.Me-
dian spot signal was used as intensitymeasure. Differentially expressed
genes in tumors expressing PD-1 were identified using SAM (signifi-
cance analyses of microarray) (False Discovery Rate b 0.001, Fold
Change N1.5). GSEA (gene set enrichment analyses) was performed ap-
plying gene sets from Molecular Signatures Database (MSigDb, version



































































Fig. 1. Expression of PD-L1 and PD-1 demonstrates no difference in survival. A, Expression of
showing PD-L1 expression. Number of cases in each group is given and number of deaths in
survival plot showing PD-1 expression. Number of cases in each group is given and number of2.5. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics
software version 25 (IBM, Armonk, NY, USA). p-Values b 0.05 were
considered statistically significant and all p-values were two-sided.
Pearson's Chi-Square test or Fisher's exact test, when appropriate,
were used for comparison between groups of categorical variables.
The log-rank test, Kaplan-Meier method was used for univariate sur-
vival analysis of time to death due to endometrial cancer (disease-
specific survival). The date of primary treatment is defined as entry.6
12 24 36 48 60
Positive PD-L1 n=407 (58)
Negative PD-L1 n=282 (53)
Length of follow-up (months)
60
Length of follow-up (months)
12 24 36 48
Positive PD-1 n=462 (63)
Negative PD-1 n=275 (52)
0.1
PD-L1 is mainly glandular and cytoplasmic, 1 bar = 10 μm. A, Kaplan-Meier survival plot
parenthesis. C, Expression of PD-1 is mainly stromal, 1 bar = 10 μm. D, Kaplan-Meier
deaths in parenthesis.
Table 2
PD-1 expression related to clinicopathological variables in 737 patients with endometrial
cancer.
Negative, n (%) Positive, n (%) p-Value⁎
Age, y 0.03
b66 130 (34) 256 (66)
≥66 145 (41) 206 (59)
FIGO 0.65
I/II 235 (38) 389 (62)
III/IV 40 (35) 73 (65)
Histologic type 0.01
Endometrioid 233 (38) 369 (61)
Non-endometrioid 42 (31) 93 (69)
Non-endometrioid types 0.01#
Clear cell 3 (12) 23 (88)
Serous 23 (36) 41 (64)
Carcinosarcomas 14 (44) 18 (56)
Undifferentiated 2 (15) 11 (85)
Histologic grade⁎⁎ 0.11
Grade 1 120 (43) 159 (57)
Grade 2 74 (36) 133 (64)
Grade 3 33 (32) 71 (68)
Myometrial infiltration 0.64
b50% 169 (37) 290 (63)
≥50% 106 (39) 169 (61)
MSI-status 0.04
Microsatellite stable 159 (40) 241 (60)
Microsatellite instable 17 (27) 47 (73)
Recurrence 0.02
Yes 62 (51) 59 (49)
No 373 (65) 199 (35)
Metastatic at primary 27 (61) 17 (38)
FIGO: International Federation of Gynecology and Obstetrics. MSI: microsatellite instable.
⁎ p-Values are calculated with Chi-Square test.
# p-Values are calculated with Fisher exact test.
⁎⁎ Endometrioid included only.
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of death.
3. Results
3.1. PD-L1 expression is independent of endometrial cancer type and grade,
and has no impact on survival
Expression patterns of PD-L1were evaluated by IHC in 689 endome-
trial cancer samples. PD-L1was expressed in 59% of primary tumors and
the staining was mainly glandular (Fig. 1A). PD-L1 expression was not
associated with any specific patient subgroup, as positive expression
of PD-L1 did not associate with age, FIGO stage, histologic type, deep
myometrial infiltration or recurrence (Table 1). No significant difference
in disease-specific survival was seen between patients with PD-L1 ex-
pression and patients with no expression of PD-L1 (Fig. 1B). No signifi-
cant impact of PD-L1 expression on disease-specific survival was seen
within the subgroup of endometrioid (5-year disease-specific survival,
positive: 95% vs. negative: 91%, p = 0.21) or non-endometrioid histol-
ogy (5-year disease-specific survival, positive: 51% vs. negative: 32%,
p = 0.74).
3.2. Positive PD-1 expression associates with non-endometrioid histology,
but not with prognosis
PD-1 expression was evaluated in 737 endometrial cancer samples
by IHC. PD-1 was expressed in 63% of primary tumors and the staining
pattern wasmainly stromal (Fig. 1C). Positive PD-1was significantly as-
sociated with low age (younger than 66; p = 0.03) and non-
endometrioid histology (p = 0.01, Table 2), but not with FIGO stage,
grade or myometrial infiltration. No difference in disease-specific sur-
vival between PD-1 positive and PD-1 negative patients was observed
(Fig. 1D). When stratifying for patients with endometrioid histology,Table 1
PD-L1 expression related to clinicopathological variables in 689 patients with endometrial
cancer.
Negative, n (%) Positive, n (%) p-Value⁎
Age, y 0.56
b66 147 (42) 203 (58)
≥66 135 (40) 204 (60)
FIGO 0.90
I/II 238 (41) 342 (59)
III/IV 44 (40) 65 (60)
Histologic type 0.17
Endometrioid 235 (42) 322 (58)
Non-endometrioid 47 (36) 85 (64)
Non-endometrioid types 0.43#
Clear cell 8 (33) 16 (67)
Serous 24 (37) 41 (63)
Carcinosarcomas 13 (42) 18 (58)
Undifferentiated 2 (17) 10 (83)
Histologic grade⁎⁎ 0.02
Grade 1 105 (40) 159 (60)
Grade 2 94 (50) 94 (50)
Grade 3 32 (33) 64 (67)
Myometrial infiltration 0.83
b50% 174 (41) 254 (59)
≥50% 107 (42) 151 (58)
MSI-status 0.24
Microsatellite stable 156 (42) 217 (58)
Microsatellite instable 30 (50) 30 (50)
Recurrence 0.5
Yes 63 (54) 53 (46)
No 318 (60) 213 (40)
Metastatic at primary 26 (62) 16 (38)
FIGO: International Federation of Gynecology and Obstetrics. MSI: microsatellite instable.
⁎ p-Values are calculated with Chi-Square test.
# p-Values are calculated with Fisher exact test.
⁎⁎ Endometrioid included only.positive PD-1 was associated with better disease-specific survival com-
pared to negative PD-1 (5-year disease-specific survival, positive: 96%
vs. negative: 89%, p = 0.02). In patients with non-endometrioid histol-
ogy PD-1 did not predict disease-specific survival (5-year disease-
specific survival, positive: 60% vs. negative: 41%, p = 0.23).
In patientswithmicrosatellite instable tumors, PD-L1 and PD-1 asso-
ciate with favorable clinical characteristics but are not related to
survival.
MSI tumors were identified by loss of one of the two mismatch-
repair proteins, MSH6 and PMS2 by IHC. Patients with MSI-tumors
have been considered better responders to checkpoint inhibitors
[13,14] and establishing PD-L1/PD-1 expression level in patients with
MSI-tumors is therefore important. InMSI-tumors PD-L1 expression as-
sociated with grade 1 tumors (p = 0.005, Supplementary Table 3),
while PD-1 expression was not associated with any clinical characteris-
tics (Supplementary Table 3). Neither PD-L1, nor PD-1 had impact on
disease-specific survival (Fig. 2A and B).
In detailed analysis comparing MSS and MSI-tumors, no difference
in expression patterns of PD-L1 and PD-1 was demonstrated (Supple-
mentary Table 4). Overall, this supports that potential responders to
PD-L1/PD-1 directed drugs are evenly distributed in the cohort.
3.3. Patients with PD-1 positive tumors show upregulation of genes associ-
ated with increased immunological activity
Patients were grouped according to PD-L1 or PD-1 status defined by
IHC, and gene expression analyses were performed. Stratifying patients
according to PD-L1 status did not result in any differentially expressed
genes between the two groups, while several genes related to immuno-
logical activity, including CD274 (encoding for PD-L1), were upregu-
lated in PD-1 positive tumors. This might suggest that expression of
PD-1 is linked to immune activation (false discovery rate; FDR b 0.001,
Fold Change N1.5 in SAM analysis, Supplementary Table 5). To further
p=0.16
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Patients with MSI-tumors Patients with MSI-tumors
Fig. 2. Expression of PD-L1 and PD-1 in MSI-tumors demonstrates no impact on survival. Kaplan-Meier survival plot for A, PD-L1 expression and B, PD-1 expression. Number of cases in
each group is given and number of deaths in parenthesis.
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expression, gene set enrichment analysis (GSEA) was performed apply-
ing gene sets from Molecular Signatures Database (MSigDb, version
6.2). Tumors with expression of PD-1 show increased immunological
activity (Supplementary Table 6) and further suggest that PD-1 is linked
to immune activation.
3.4. Heterogeneous expression of PD-L1 and PD-1 from primary tumors to
metastatic lesions
Protein expression was investigated in corresponding primary and
metastatic lesions by IHC. A detailed overview of expression in individ-
ual patients and individualmetastases is given in Fig. 3G. For PD-L1, 275
metastases from 68 patients were investigated (Fig. 3A–C). In primary
tumors, 77% of these patients expressed PD-L1 (Fig. 3A). Only 40%
(n = 21) expressed PD-L1 in all investigated metastatic lesions, while
21% (n= 11) of patients had lesions that were both positive and nega-
tive for PD-L1 (Fig. 3B). However, 39% (n = 20) of the patients did not
express PD-L1 in any metastatic lesion, in spite of being positive in the
primary setting (Fig. 3B). In patients with PD-L1 negative primary tu-
mors (Fig. 3C), 38% (n = 6) of the patients remained negative also in
the metastatic setting. However, 31% (n = 5) of the patients had PD-
L1 positive metastatic lesions and 31% (n = 5) of the patients had
both negative and positive metastatic lesions (Fig. 3C).
273 metastases from 74 patients were investigated for protein ex-
pression of PD-1 (Fig. 3D–F). PD-1 was expressed in 70% of primary tu-
mors (Fig. 3D). Amongpatientswith PD-1 positive primary tumors, only
27% (n=14) remained positive in all metastatic lesionswhile 21% (n=
11) had both positive and negativemetastasis (Fig. 3E). In 52% (n=27)
PD-1 expressionwas lost from primary tometastatic lesions (Fig. 3E). In
patients with primary tumors with no expression of PD-1 (37%)
(Fig. 3F), no patients showed expression of PD-1 in the metastatic le-
sions, as all metastatic lesions investigated were negative for PD-1.
When examining all patients investigated in this study, 68% (n = 49)
of all patients were negative for PD-1 in the metastatic lesions.
The high degree of discordant expression between biopsies from the
primary tumor and corresponding metastatic lesions, and between
multiple metastases from the same patient (Fig. 3G), depicts potential
response in so far unidentified patient groups, and suggests investiga-
tion of protein expression in metastases when assigning patients for
PD-L1 and PD-1 inhibitors.4. Discussion
In the present study we investigated a large, population based and
prospectively collected cohort of endometrial cancer.Wedepict expres-
sion of PD-L1 in 59% of patients and PD-1 in 63% of patients. We find
that neither PD-L1 nor PD-1 is associated with prognosis, neither in
the overall patient group, nor in subgroups of endometrioid or non-
endometrioid cancers. PD-L1 was not associated with any clinical char-
acteristics. Expression of PD-L1 has been reported to range from 14% to
36% [18–20], and has been associated with non-endometrioid histology
and lymphovascular space invasion, but found no association with sur-
vival [18–20]. Results from recent studies investigating the expression
patterns of PD-1 in endometrial cancer are also conflicting, with results
ranging from16% to 60% PD-1 positive patients [18,19]. In our study, ex-
pression of PD-1 in the overall cohort was significantly associated with
low age (p = 0.01) and non-endometrioid histology (p = 0.03). Other
studies report that negative PD-1 is associated with poor differentiation
and non-endometrioid histology [18,19]. In regards to survival, no asso-
ciationwith survival has previously been reported, which is in linewith
our findings [19]. Our results concur with previous findings from
smaller cohortswhich state that PD-L1 and PD-1 have no impact on sur-
vival, however results are inconsistent regarding association with clini-
cal characteristics.
Inconsistent reports on fraction of positive tumor cells [26], as well
as studies demonstratingdifferenceswhen comparing biomarker assays
for PD-L1 have raised concerns [27]. In the clinical context, the main
concern is to ascertain that patients who could benefit from immune
checkpoint inhibitors are identified and to keep the number of false-
negative cases as low as possible, at the same time avoid false-positive
tests and over-treatment with potentially severe side effects. In our
study, we used validated antibodies that have previously been used in
several publications [28,29]. It is also evident that expression of PD-L1
determined in small tissue biopsies might not be representative of the
full tumor specimen. The use of TMAs for evaluating expression of PD-
L1 and PD-1 may be a potential bias, and as for all biomarkers clinical
implementation relies on validation on full sections [30]. However, pre-
vious studies have demonstrated a good sensitivity for detection of PD-
L1 in TMAs when using our method of three tissue cylinders [31]. Fur-
ther studies using large patient samples and preferably biomarker inclu-
sion in clinical trials are vital to establish the robustness of these
markers.
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Fig. 3. Expression of PD-L1 and PD-1 inmetastatic lesions. A, 77% of lesionswere PD-L1 positive in primary lesions. B, Histogram showing PD-L1 status from PD-L1 positive primary tumors
and C, PD-L1 status in PD-L1 negative primary tumors. D, 70% of patients were PD-1 positive in primary lesions. E, Histogram showing PD-1 status in PD-1 positive tumors and F, PD-1
negative primary tumors. G, Expression patterns in individual metastases from patients with PD-L1 positive (dark blue), PD-L1 negative (light blue), PD-1 positive (dark green) and
PD-1 negative (light green). The primary tumor is illustrated with a bar. One circle represents one metastasis.
265H. Engerud et al. / Gynecologic Oncology 157 (2020) 260–267Immune checkpoint inhibitors have been suggested for treatment of
patients with advanced or recurrent MSI-high, but the fraction of PD-L1
and PD-1 positive patients within this subgroup is still not clearly de-
fined. We here validate the previous observation that neither PD-L1,
nor PD-1 have prognostic value in theMSI subgroup. However, previous
studies have shown more frequent expression of PD-L1 in MSI tumors
compared to MSS tumors [20,32]. Expression of PD-L1 and PD-1 wassimilar in MSI and MSS tumors in our cohort and no significant differ-
enceswere found in expression patterns. Recent clinical studies indicate
that treatment with immune checkpoint inhibitors may not be exclu-
sively for patients with MSI tumors [16,17]. The robustness of PD-L1
and PD-1 as predictive markers for response to immune checkpoint in-
hibitors are debated as studies have shown a variable predictive value of
PD-L1 [6,33]. Interestingly, gene expression analyses of all patients with
266 H. Engerud et al. / Gynecologic Oncology 157 (2020) 260–267expression of PD-1 identified upregulated genes related to immune ac-
tivity, including the gene CD274 (encoding for PD-L1). This might sug-
gest that patients with expression of PD-1 may be responders to
immune checkpoint inhibitors, regardless ofMSI/MSS status. Clinical tri-
als are needed to further elucidate the role of PD-L1 and PD-1 as predic-
tive markers in endometrial cancer. In a recent biomarker-unselected
trial combining pembrolizumab and lenvatinib multikinase inhibitor of
VEGFR1–3 in metastatic endometrial cancer, an objective response
was recorded in 16/45 patients with MSS-tumors compared to two out
of four MSI-tumors [16]. Also, a study testing combination therapy
with dostarlimab (PD-1-inhibitor) and chemotherapy (carboplatin and
paclitaxel), regardless of MSI-status (NCT03981796) is in the pipeline
and the results from this trial will hopefully suggest if also MSS patients
are responders.
Immune checkpoint inhibitors to PD-1 in endometrial cancer has so
far been approved in the recurrent and advanced setting only [5], how-
ever, expression patterns inmetastases of endometrial cancers have not
previously been investigated. This study finds discordant expression of
PD-L1 and PD-1 in primary tumors compared to corresponding meta-
static lesions, and a substantial number of the metastases have an
intra-variable expression of PD-L1 or PD-1 (see Fig. 3G). Previous stud-
ies have found frequent expression of PD-L1 in metastatic colorectal
cancer compared to primary tumors and an increase of PD-L1 during
disease progression [34]. Also, discordant expression between primary
tumors and correspondingmetastatic lesions has previously been dem-
onstrated in breast cancer, malignant melanoma and head and neck
cancers [35–37]. It is interesting to note that among patients that were
positive for PD-L1 and/or PD-1 in the primary tumor, we find that ex-
pression was lost in 39% (n = 20) of patients with PD-L1 positive pri-
mary tumors and in 52% (n = 27) of patients with PD-1 positive
tumors. Treatment with pembrolizumab to PD-L1 positive, advanced
endometrial cancer patients has previously demonstrated durable anti-
tumor activity [6]; however, a variation in response was noted and het-
erogeneity was deemed as a possible explanation for the lack of
response. The observed variation in PD-L1 and PD-1 expression in the
metastases might thus be relevant for the response to treatment, also
in endometrial cancer. PD-L1/PD-1 points to the need for evaluation of
response markers in metastases when treating recurrent or advanced
disease, as expression is heterogeneous and may be discordant for pri-
mary tometastatic lesions. Future studies exploring PD-L1 and PD-1 ex-
pression inmetastatic lesions prior to treatmentwould be interesting to
further pinpoint if these biomarkers really can predict response to
checkpoint inhibitors.
In the present study, we demonstrate frequent expression of PD-L1
and PD-1 in endometrial cancer, and expression patterns are similar
across MSS and MSI tumors. We identify a high number of positive
PD-L1 tumors in our series, with 59% of all patients being positive for
PD-L1 and 63% positive for PD-1. This inconsistency in the literature re-
garding frequency of PD-L1 and PD-1 expression may be explained by
different antibodies and/or cut-offs for expression, and points to the im-
portance of robust biomarkers and specific guidelines for expression
evaluation. In corresponding metastatic lesions, expression is inconsis-
tent and intra-variable compared to primary tumors and this should
be considered when treatment strategies are decided. More research
is needed to identify patients who may respond from immune check-
point inhibitors to in endometrial cancer.
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